• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

Exelixis

NASDAQ:EXEL

$4.61 $0.03 (0.66%)

REAL-TIME: Last trade at

Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 1

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA)

Exelixis' Management Presents at Bank of America Merrill Lynch 2012 Health Care Conference (Transcript)

Ariad Pharmaceuticals, ArQule, Exelixis, Aveo, Other Cancer Drug Stocks Fall

ASCO '12 Abstract Dump: Cancer Stocks in Focus

Reminder: Exelixis Announces Data Presentations, Webcast of Investor Briefing in Conjunction With 2012 ASCO Annual Meeting

Reminder: Exelixis Announces Data Presentations, Webcast of Investor Briefing in Conjunction With 2012 ASCO Annual Meeting

Exelixis Announces May 17th Webcast of Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference

Exelixis Announces May 17th Webcast of Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference

Taking An Early Look at 2012 ASCO Biotech/Cancer Stocks (DNDN, LLY, ARIA, ARRY, BVTI, ABPI, CLDX, CYTR, GALE, EXEL, GNBT, GHDX, IMGN, NKTR, NLNK, PCYC, SGEN)

Exelixis' Management Presents at Deutsche Bank Securities Annual Health Care Conference (Transcript)

Exelixis risk/reward favorable at current levels, says Maxim

Biotech Stock Mailbag: Exelixis, Protalix, Arena

Exelixis Announces First Quarter 2012 Financial Results

Exelixis's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Exelixis reports Q1 EPS (18c), consensus (17c)

Exelixis, Inc. (EXEL) Misses Q1 EPS by 1c

Exelixis Announces May 8th Webcast of Presentation at the Deutsche Bank Securities 37th Annual Health Care Conference

Exelixis: Uncovering Value

Pharmaceutical Companies Look To Biotech Industry To Combat Losses From Expiring Patents

Welcome to the Exelixis Discussion forum on AGORACOM

Pharmaceutical Companies Look to Biotech Industry to Combat Losses From Expiring Patents

Maxim Group Starts Exelixis (EXEL) at Buy

Exelixis Announces May 3rd Webcast of First Quarter 2012 Financial Results Conference Call

Exelixis initiated with a Buy at Maxim

Exelixis Announces May 3rd Webcast of First Quarter 2012 Financial Results Conference Call

10 Stocks That Could Rise in Market Decline

Lazard Capital to host a bus tour

Cabozantinib to be Featured in Nine Presentations at 2012 ASCO Annual Meeting

Lightning Round: Exelixis, Oracle, Kohl's and More

Exelixis coverage resumed with a Buy at Stifel Nicolaus

Exelixis' CEO Presents at Lazard Capital Market 8th Annual Healthcare Conference (Transcript)

Exelixis announces initiation of trial combining cabozantinib, abiraterone

Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial Combining Cabozantinib and Abiraterone in Men With Castration-Resistant Prostate Cancer

Exelixis Announces March 6 Webcast of Presentation at the Cowen Health Care Conference

Exelixis' CEO Presents at Citi Global Health Care Conference (Transcript)

Cancer Treatments Evolve - Exelixis and Seattle Genetics Look to Lead

Cancer Treatments Evolve - Exelixis and Seattle Genetics Look to Lead

Dual Inhibition of MET and VEGF Signaling With Cabozantinib Blocks Tumor Invasiveness and Metastasis

Exelixis Announces February 28 Webcast of Presentation at the Citi Global Health Care Conference

See More Articles...